Biotech & Healthcare Archives - Vista Partners LLC

Precision Meets Possibility: Inside Tribe Public’s Latest CEO Event on Targeted Alpha Therapy with NAYA

by John F. Heerdink, Jr. 7 hours ago 127Views 0Likes

In a market often dominated by macro noise and earnings volatility, Tribe Public’s latest CEO Presentation and Q&A Webinar Event offered something far rarer: a glimpse into the future of cancer treatment—and perhaps, a pathway to curing it. The event, titled “Can…

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

by John F. Heerdink, Jr. 1 day ago 101Views 0Likes

Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. 1 day ago 92Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

From Shots to Patch Pumps: How Eli Lilly and Modular Medical Are Quietly Repricing Metabolic Risk -( $LLY $MODD )

by John F. Heerdink, Jr. 4 days ago 302Views 0Likes

Eli Lilly’s (LLY) CEO is positioning the weight‑loss boom as a long runway that extends well beyond today’s GLP‑1 headlines, and a tiny pump maker may have just found itself a VIP seat on the same flight. The Second Act of the…

Tribe Public Shines a Spotlight on Naya Therapeutics as Next-Gen Oncology Steps Onto the Investor Stage

by John F. Heerdink, Jr. 5 days ago 232Views 0Likes

Tribe Public’s latest CEO event video, titled “Can Targeted Alpha Therapy Cure Cancer” brings Naya Therapeutics to center stage in a format that feels more like a well-curated Wall Street salon than a standard biotech webinar. The Tribe model—investor-driven CEO access in…

Hims & Hers, RFK Jr., And A Market Suddenly Bullish On Peptides (With A ‘Pivot’ In Diabetes Care) – ( $HIMS $MODD )

by John F. Heerdink, Jr. April 16, 2026 305Views 0Likes

Wall Street woke up to a rare sight this week: peptides moving out of the regulatory penalty box and straight into the growth-stock conversation. Hims & Hers Health Inc. (NYSE: HIMS) extended its recent rally after U.S. Health and Human Services Secretary…

Tribe Public Hosts Exclusive CEO Event: “Can Targeted Alpha Therapy Cure Cancer?”

by John F. Heerdink, Jr. April 13, 2026 124Views 0Likes

In the ever-evolving world of oncology innovation, a bold question is being asked: “Can Targeted Alpha Therapy Cure Cancer?” That’s the headline theme of Tribe Public’s next CEO Presentation and Q&A Webinar, scheduled for Tuesday, April 14, 2026, at 8 a.m. PT / 11 a.m.…

Diabesity’s New Plus‑One: FDA Gives Green Light to Modular Medical’s Pivot Patch Pump -( $MODD $LLY $NVO )

by John F. Heerdink, Jr. April 9, 2026 423Views 0Likes

Modular Medical’s (NASDAQ: MODD) latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. Pivot Patch Pump Gets…

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

by John F. Heerdink, Jr. April 8, 2026 259Views 0Likes

The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…

Medicare’s Money Surprise: Why UnitedHealth and Humana Just Got a Policy Pay Raise -( $CNC $CVS $ELV $HUM $MOH $UNH )

by John F. Heerdink, Jr. April 7, 2026 234Views 0Likes

UnitedHealth just got the policy equivalent of a surprise bonus check from Washington — and Wall Street is cashing it just as fast as the insurers are. Medicare’s Big Reveal: From Nail-Biter to Tailwind For months, Medicare Advantage insurers had been bracing…

Biotech & Healthcare

Your Guide To Staying Informed In The Markets